CN102048706A - Darifenacin hydrobromide sustained-release tablet and preparation method - Google Patents
Darifenacin hydrobromide sustained-release tablet and preparation method Download PDFInfo
- Publication number
- CN102048706A CN102048706A CN 201110005318 CN201110005318A CN102048706A CN 102048706 A CN102048706 A CN 102048706A CN 201110005318 CN201110005318 CN 201110005318 CN 201110005318 A CN201110005318 A CN 201110005318A CN 102048706 A CN102048706 A CN 102048706A
- Authority
- CN
- China
- Prior art keywords
- carbomer
- darifenacin hydrobromide
- sustained release
- release tablets
- darifenacin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of new medicament technologies, and in particular relates to a darifenacin hydrobromide sustained-release tablet and a preparation method. The darifenacin hydrobromide sustained-release tablet adopts carbomer as a new retardant, and the dosage of the carbomer is 1-5% by weight of the preparation and can reach considerable vitro release and bioavailability compared with the dosage of the retardant in the prior art, which is more than half of the dosage of a prescription. The dosage of the retardant in the new method is greatly reduced so that the consumption of materials can be greatly reduced, the process is simpler, the controllability is better, the efficiency is improved, and the production cost is greatly reduced.
Description
Technical field
The invention belongs to the medicine new technical field, be specifically related to a kind of darifenacin hydrobromide sustained release tablets and preparation method that adopts carbomer as blocker.
Background technology
Darifenacin hydrobromide sustained release tablets is used for the treatment of bladder hyperkinesia diseases (OAB) such as urinary incontinence, urgent micturition and frequent micturition, and U.S. FDA is in the darifenacin hydrobromide sustained release tablets (Enablex of December in 2004 approval on the 22nd Novartis
) listing.Darifenacin plays a role by blocking main M3 receptor to the bladder muscle contractile response, it is the deep alkali receptor blocking agent of potent poison, help to alleviate the incidence rate of urinary incontinence, increase bladder urine reserves, reduce number of micturitions and reduce the constriction and the urgency of being eager to urinate.The M3 of darifenacin hydrobromide acts in all OAB medicines has uniqueness, makes the incidence rate that slow releasing tablet can reduce nervus centralis and cardiovascular adverse effects.
The open Enablex of the orange book of U.S. FDA (Orange Book)
Be to adopt the formulation and technology of patent US6106864 to be prepared, it adopts high-molecular weight hypromellose as blocker, the large usage quantity of hypromellose, and the ratio that accounts for the tablet total weight amount is up to 56 ~ 58%.Though said method has reached ideal external slow release effect and bioavailability, but the use of high weight and a high proportion of blocker had both caused the increase greatly of the consumption of material, thereby had increased cost, make that also the adjustable space of prescription is less, the production poor controllability.
Summary of the invention
Purpose of the present invention is exactly the defective at above-mentioned existence, provides a kind of novel blocker to be used to prepare the method for darifenacin hydrobromide sustained release tablets.
Use novel adjuvant carbomer as blocker, only account for 1% ~ 5% of weight of formulation, for example: consumption only is 1mg ~ 5mg, and sheet heavily is 100mg; Perhaps the carbomer consumption only is 2mg ~ 10mg, and sheet heavily is 200mg, can reach release in vitro effect and the bioavailability suitable with existing method.Because the minimizing significantly of the consumption of blocker in the new method, can reduce the consumption of material, also make the prescription adjustability obviously strengthen, thereby can make technology simpler, controllability is better, and efficient improves, and production cost significantly reduces.
Darifenacin hydrobromide sustained release tablets of the present invention adopts novel blocker carbomer, consumption only accounts for 1% ~ 5% of weight of formulation, adopt the calcium hydrogen phosphate of compressibility and lactose as diluent simultaneously, magnesium stearate is as lubricant, and adopts powder mixes direct compression technology.
Technical scheme of the present invention is: a kind of darifenacin hydrobromide sustained release tablets, adopt the blocker of carbomer as slow releasing preparation.
1% ~ 5% of described blocker carbomer comprises weight of formulation.
Described a kind of darifenacin hydrobromide sustained release tablets comprises following drug component by weight:
Darifenacin hydrobromide 1%-20%;
Carbomer 1%-5%;
Calcium hydrogen phosphate 16%-91%;
Lactose 5%-51%;
Magnesium stearate 0.1%-10%.
Adopt powder mixes direct compression technology to be prepared darifenacin hydrobromide sustained release tablets of the present invention, may further comprise the steps:
1. darifenacin hydrobromide, calcium hydrogen phosphate, carbomer, lactose are sieved mix homogeneously;
2. get magnesium stearate and add above powder, mixing;
3. adopt powder mixes direct compression technology, the heavy and pressure of adjustment sheet, tabletting, coating.
Beneficial effect of the present invention is: use novel adjuvant carbomer as blocker, only account for 1% ~ 5% of weight of formulation, for example: consumption only is 1mg ~ 5mg, and sheet heavily is 100mg; Perhaps the carbomer consumption only is 2mg ~ 10mg, and sheet heavily is 200mg, can reach release in vitro effect and the bioavailability suitable with existing method.Because the minimizing significantly of the consumption of blocker, can reduce the consumption of material, also make the prescription adjustability obviously strengthen, reduced production cost simultaneously, enhance productivity.
Technology of the present invention in addition adopts the calcium hydrogen phosphate of compressibility and lactose as diluent simultaneously, and magnesium stearate is as lubricant, and preparation technology is simple for prescription, be easy to put into production, the powder flowbility that makes is better, and be more than 36 degree angle of repose, can satisfy the requirement of high speed tabletting in tablet manufacture, the tablet hardness of compacting is better, good looking appearance, technology is simple, and controllability is good, efficient improves, and production cost significantly lowers.
The specific embodiment:
In order to understand the present invention better, describe technical scheme of the present invention in detail with instantiation below, but the present invention is not limited thereto.
Embodiment 1
Darifenacin hydrobromide 8.93g
Carbomer 974P 5.6g
Calcium hydrogen phosphate 133.47g
Lactose 50.0g
Magnesium stearate 2.0g
Gross weight 200g
Make 1000
Darifenacin hydrobromide, carbomer 974P, calcium hydrogen phosphate and lactose are crossed 80 mesh sieves, the three-dimensional mixer mix homogeneously.Magnesium stearate lubricant is added above powder, mix homogeneously in three-dimensional mixer, stomach dissolution type coating powder coating is used in the stamping of f8mm scrobicula.
Embodiment 2
Darifenacin hydrobromide 8.93g
Carbomer 971P 2g
Calcium hydrogen phosphate 137.07g
Lactose 50.0g
Magnesium stearate 2.0g
Gross weight 200g
Make 1000
Darifenacin hydrobromide, carbomer 971P, calcium hydrogen phosphate and lactose are crossed 80 mesh sieves, the three-dimensional mixer mix homogeneously.Magnesium stearate lubricant is added above powder, mix homogeneously in three-dimensional mixer, stomach dissolution type coating powder coating is used in the stamping of f8mm scrobicula.
Embodiment 3
Darifenacin hydrobromide 8.93g
Carbomer 934 P 10g
Calcium hydrogen phosphate 129.07g
Lactose 50.0g
Magnesium stearate 2.0g
Gross weight 200g
Make 1000
Darifenacin hydrobromide, carbomer 934 P, calcium hydrogen phosphate and lactose are crossed 80 mesh sieves, the three-dimensional mixer mix homogeneously.Magnesium stearate lubricant is added above powder, mix homogeneously in three-dimensional mixer, stomach dissolution type coating powder coating is used in the stamping of f8mm scrobicula.
Embodiment 4
Darifenacin hydrobromide 17.86g
Carbomer 974P 5.6g
Calcium hydrogen phosphate 124.54g
Lactose 50.0g
Magnesium stearate 2.0g
Gross weight 200g
Make 1000
Darifenacin hydrobromide, carbomer 974P, calcium hydrogen phosphate and lactose are crossed 80 mesh sieves, the three-dimensional mixer mix homogeneously.Magnesium stearate lubricant is added above powder, mix homogeneously in three-dimensional mixer, stomach dissolution type coating powder coating is used in the stamping of f8mm scrobicula.
Embodiment 5
Darifenacin hydrobromide 17.86g
Carbomer 971P 2g
Calcium hydrogen phosphate 128.14g
Lactose 50.0g
Magnesium stearate 2.0g
Gross weight 200g
Make 1000
Darifenacin hydrobromide, carbomer 971P, calcium hydrogen phosphate and lactose are crossed 80 mesh sieves, the three-dimensional mixer mix homogeneously.Magnesium stearate lubricant is added above powder, mix homogeneously in three-dimensional mixer, stomach dissolution type coating powder coating is used in the stamping of f8mm scrobicula.
Embodiment 6
Darifenacin hydrobromide 17.86g
Carbomer 934 P 10g
Calcium hydrogen phosphate 120.14g
Lactose 50.0g
Magnesium stearate 2.0g
Gross weight 200g
Make 1000
Darifenacin hydrobromide, carbomer 934 P, calcium hydrogen phosphate and lactose are crossed 80 mesh sieves, the three-dimensional mixer mix homogeneously.Magnesium stearate lubricant is added above powder, mix homogeneously in three-dimensional mixer, stomach dissolution type coating powder coating is used in the stamping of f8mm scrobicula.
Embodiment 7
Darifenacin hydrobromide 8.93g
Carbomer 974P 2.8g
Calcium hydrogen phosphate 61.77g
Lactose 25.5g
Magnesium stearate 1.0g
Gross weight 100g
Make 1000
Darifenacin hydrobromide, carbomer 974P, calcium hydrogen phosphate and lactose are crossed 80 mesh sieves, the three-dimensional mixer mix homogeneously.Magnesium stearate lubricant is added above powder, mix homogeneously in three-dimensional mixer, stomach dissolution type coating powder coating is used in the stamping of f8mm scrobicula.
Embodiment 8
Darifenacin hydrobromide 17.86g
Carbomer 974P 2.8g
Calcium hydrogen phosphate 52.84g
Lactose 25.5g
Magnesium stearate 1.0g
Gross weight 100g
Make 1000
Darifenacin hydrobromide, carbomer 974P, calcium hydrogen phosphate and lactose are crossed 80 mesh sieves, the three-dimensional mixer mix homogeneously.Magnesium stearate lubricant is added above powder, mix homogeneously in three-dimensional mixer, stomach dissolution type coating powder coating is used in the stamping of f8mm scrobicula.
Embodiment 9
Release relatively
Darifenacin hydrobromide sustained release tablets (the Enablex that embodiment 1-8 and Novartis Co.,Ltd produce
) carry out the release in vitro degree relatively.According to drug release determination method (two appendix X of Chinese Pharmacopoeia version in 2005 D, first method), adopt the device of dissolution method (two appendix X of Chinese Pharmacopoeia version in 2005 C, second method), as release medium, rotating speed is 100 rev/mins with the hydrochloric acid of 900ml0.01mol/L, in accordance with the law operation.Through 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 16 hours, 20 hours, 24 hours, get solution 10ml(respectively and in time in operating instrument, replenish release medium 10ml), filter, get subsequent filtrate, as need testing solution; It is an amount of that other gets the darifenacin hydrobromide reference substance, accurate claims surely, is dissolved in water and dilutes and make the solution that contains darifenacin 8.3 μ g among every 1ml approximately, in contrast product solution.
With the octadecylsilane chemically bonded silica is filler; (with triethylamine adjust pH to 6.0)-methanol (40:60) is mobile phase, 25 ℃ of column temperatures, flow velocity 1.0ml with the 0.05mol/l potassium dihydrogen phosphate; The detection wavelength is 228nm.Precision is measured each 20 μ l of above solution, injecting chromatograph, and the record chromatogram is with every burst size at different time of calculated by peak area.Result of the test sees Table 1.
Table 1 embodiment 1-8 and listing product (Enablex
) the release in vitro degree relatively
* the f2 factorization method is to estimate the method for the similarity of stripping curve, if tried and the stripping curve of reference preparation between the f2 value be not less than 50, think that then both are similar.
As can be seen from the above table, embodiment 1～8 uses the darifenacin hydrobromide sustained release tablets (Enablex that the darifenacin hydrobromide sustained release tablets of 1% ~ 5% carbomer preparation can be produced with the Novartis Co.,Ltd of having gone on the market
) have a suitable release in vitro degree.
Embodiment 10
Bioavailability relatively
Darifenacin hydrobromide sustained release tablets (the Enablex of the tablet of embodiment 4 (A medicine) and Novartis Co.,Ltd
, the R medicine)
Self front and back 3 * 2 trial design is adopted in test.6 Beagle Canis familiaris L.s, each 3 of male and female, about 1 age, regular grade, the body weight 6.2 ~ 6.5kg when being used to test.Be divided into 2 groups by body weight, every group of 3 animals are established test sample (A medicine group) and reference substance (R medicine group), fasting 16 hours.Administration is 2 times altogether, and the 1st administration at interval 2 all cleaning phases, carried out medicine the 2nd time after also gathering the biological sample that finishes.Adopt 3 * 2 to intersect administration to reduce the influence that animal individual difference causes result of the test.Dosage is 4mg/kg.
0.5h, 1h before the administration and after the administration, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h,
, 36h gathers venous blood 1.5ml, anticoagulant heparin, 3000r/min is centrifugal, gets blood plasma and preserves in-80 ℃ and be equipped with inspection.2 weeks were cleaned after date, and two treated animal cross matchings are collected as stated above.Result of the test sees Table 2.
The bioavailability AUC of the tablet of table 2 embodiment 4 (A medicine) and listing product (Enablex, R medicine) and relative bioavailability thereof and main pharmacokinetic parameter Cmax and ratio thereof
Experimental result shows: average blood drug level-time changing curve was all close after beasle dog per os filling stomach gave A medicine and R medicine 4mg/kg, and the main pharmacokinetic parameter (mean+SD) of test sample A medicine and reference substance R medicine is respectively T
1/2: 6.79 ± 2.695 h and 6.521 ± 2.686 h, C
Max: 127.322 ± 112.703 ng/ml and 125.925 ± 101.827 ng/ml, AUC
0-t: 591.733 ± 475.623 μ gL
-1H and 607.711 ± 478.232 μ gL
-1H, T
MaxBe 6.00 h.The A medicine is 99.7 ± 13.5% with respect to the bioavailability of R medicine.
Data show, the darifenacin hydrobromide sustained release tablets (Enablex that preparation provided by the invention and the Novartis Co.,Ltd of having gone on the market produce
) bioequivalence that has.
Claims (6)
1. a darifenacin hydrobromide sustained release tablets is characterized in that, adopts the blocker of carbomer as slow releasing tablet.
2. darifenacin hydrobromide sustained release tablets according to claim 1 is characterized in that, 1% ~ 5% of described blocker carbomer comprises weight of formulation.
3. darifenacin hydrobromide sustained release tablets according to claim 1, carbomer are selected from one or more among carbomer 974P, carbomer 971P, the carbomer 934 P.
4. according to claim 1 or the described darifenacin hydrobromide sustained release tablets of 3 arbitrary claim, it is characterized in that the preferred carbomer 974P of described carbomer.
5. darifenacin hydrobromide sustained release tablets according to claim 1 is characterized in that, comprises the drug component by following weight ratio:
Darifenacin hydrobromide 1%-20%;
Carbomer 1%-5%;
Calcium hydrogen phosphate 16%-91%
Lactose 5%-50%;
Magnesium stearate 0.1%-10%.
6. prepare the method for the described darifenacin hydrobromide sustained release tablets of claim 1, it is characterized in that, adopt powder mixes direct compression technology to be prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100053185A CN102048706B (en) | 2011-01-12 | 2011-01-12 | Darifenacin hydrobromide sustained-release tablet and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100053185A CN102048706B (en) | 2011-01-12 | 2011-01-12 | Darifenacin hydrobromide sustained-release tablet and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102048706A true CN102048706A (en) | 2011-05-11 |
| CN102048706B CN102048706B (en) | 2012-02-22 |
Family
ID=43953730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100053185A Active CN102048706B (en) | 2011-01-12 | 2011-01-12 | Darifenacin hydrobromide sustained-release tablet and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102048706B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579379A (en) * | 2011-12-29 | 2012-07-18 | 北京科信必成医药科技发展有限公司 | Drug sustained-release preparation and method for preparing same |
| CN102600096A (en) * | 2011-12-29 | 2012-07-25 | 北京科信必成医药科技发展有限公司 | Darifenacin sustained release preparation and preparation method thereof |
| CN106420647A (en) * | 2016-10-13 | 2017-02-22 | 山东创新药物研发有限公司 | Sustained-release preparation containing darifenacin hydrobromide and preparation of sustained-release preparation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1195984A (en) * | 1995-09-15 | 1998-10-14 | 辉瑞研究及发展公司 | Pharmaceutical formulations containing darifenacin |
| US20030185882A1 (en) * | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
| CN1604777A (en) * | 2001-12-14 | 2005-04-06 | 诺瓦提斯国际药物有限公司 | Method of treatment |
-
2011
- 2011-01-12 CN CN2011100053185A patent/CN102048706B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1195984A (en) * | 1995-09-15 | 1998-10-14 | 辉瑞研究及发展公司 | Pharmaceutical formulations containing darifenacin |
| US20030185882A1 (en) * | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
| CN1604777A (en) * | 2001-12-14 | 2005-04-06 | 诺瓦提斯国际药物有限公司 | Method of treatment |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579379A (en) * | 2011-12-29 | 2012-07-18 | 北京科信必成医药科技发展有限公司 | Drug sustained-release preparation and method for preparing same |
| CN102600096A (en) * | 2011-12-29 | 2012-07-25 | 北京科信必成医药科技发展有限公司 | Darifenacin sustained release preparation and preparation method thereof |
| CN102600096B (en) * | 2011-12-29 | 2016-08-10 | 北京科信必成医药科技发展有限公司 | A kind of darifenacin slow releasing preparation and preparation method thereof |
| CN102579379B (en) * | 2011-12-29 | 2016-08-10 | 北京科信必成医药科技发展有限公司 | A kind of medicament slow release preparation and preparation method thereof |
| CN106420647A (en) * | 2016-10-13 | 2017-02-22 | 山东创新药物研发有限公司 | Sustained-release preparation containing darifenacin hydrobromide and preparation of sustained-release preparation |
| CN106420647B (en) * | 2016-10-13 | 2019-11-22 | 山东创新药物研发有限公司 | A kind of sustained release preparation and preparation method thereof containing darifenacin hydrobromide |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102048706B (en) | 2012-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105769792A (en) | A tablet containing a 1-(beta-D-glucopyranosyl)-3-(phenylthienylmethyl)benzene compound | |
| WO2022022369A1 (en) | Sustained-release formulation of tofacitinib or salt thereof and preparation method therefor | |
| CN106924208A (en) | A kind of compound Dapagliflozin Metformin Extended-release Tablets and preparation method thereof | |
| CN112641742B (en) | Sacubitril valsartan sodium sustained-release tablet and preparation method thereof | |
| CN103316026B (en) | Contain joint product of Phentermine and Topiramate and preparation method thereof | |
| CN102048706B (en) | Darifenacin hydrobromide sustained-release tablet and preparation method | |
| CN111514142B (en) | Pharmaceutical composition containing nitroxoline prodrug and preparation method and application thereof | |
| CN109662950A (en) | A kind of pharmaceutical composition containing dapoxetine hydrochloride | |
| CN103099790A (en) | Tablet containing everolimus and preparation method thereof | |
| CN107753455B (en) | A tablet containing imidafenacin and its preparation method | |
| CN109833309A (en) | Memantine is sustained microplate capsule and preparation method thereof | |
| CN106924237B (en) | It is a kind of containing En Gelie is net and the pharmaceutical composition of Metformin hydrochloride | |
| CN101856498B (en) | Anti-septic shock medicine composition and application thereof | |
| CN103690506B (en) | Trospium chloride slow-release composition and preparation method thereof | |
| CN102772395A (en) | Sustained release preparation containing ambroxol hydrochloride and clenbuterol hydrochloride, and preparation method thereof | |
| CN102462667B (en) | Clopidogrel bisulfate tablet | |
| KR101587140B1 (en) | Capsule containing mini-tablets comprising mosapride citrate for sustained-releasing formulation improving gastrointestinal disease and preparing the method thereof | |
| CN102293759A (en) | Dextral ibuprofen sustained release tablet preparation and preparation method thereof | |
| CN104523642A (en) | Metoprolol sustained-release tablet and preparation method thereof | |
| CN112472675B (en) | Sparapage tablet and preparation method thereof | |
| CN104434852A (en) | Famciclovir direct compressed tablet and preparation method thereof | |
| CN103301089B (en) | Famciclovir capsule preparation and preparation method thereof | |
| CN107149597A (en) | A kind of preparation method of metroprolol succinate sustained-release compaction of pellet | |
| CN101756939B (en) | Dexketoprofen coating sustained-release micro-encapsulated capsule | |
| CN104288127A (en) | Allopurinol sustained release capsule and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |